First‑Line Management of Postmenopausal Vaginal Dryness

Local Low‑Dose Vaginal Estrogen (Strong Recommendation)

Local low‑dose vaginal estrogen is recommended as the first‑line hormonal therapy for postmenopausal women with vaginal dryness, providing strong effectiveness and a high safety margin; formulations (cream, tablet, or ring) should be individualized according to patient dexterity, anatomy, and preference. 1
This therapy significantly improves vaginal dryness, dysuria, dyspareunia, and overall vulvovaginal discomfort. 1
When used without a progestogen, low‑dose vaginal estrogen does not raise systemic estradiol levels and does not increase the risk of endometrial hyperplasia or cancer. 1
Recommended dosing for estradiol tablets: daily application for a 2‑week loading phase, then twice‑weekly maintenance (e.g., Tuesdays and Fridays) to maintain benefit while minimizing systemic exposure. 3
Clinical improvement typically begins within 2–3 weeks and continues to normalize symptoms through 12 weeks of therapy. 4

Vaginal DHEA produces statistically significant reductions in vulvovaginal dryness and dyspareunia compared with placebo. 1
Additional benefits include enhanced sexual function, lower vaginal pH, and improved epithelial architecture. 1
It is especially useful for women already receiving systemic estrogen who require supplemental local therapy. 1

Ospemifene may be considered for vulvovaginal dryness and dyspareunia when estrogen and DHEA are unsuitable, but it carries notable safety concerns. 1
The FDA has issued a boxed warning for endometrial thickening/stimulation, increased stroke risk, and deep‑vein thrombosis. 1

Vaginal moisturizers applied at least twice weekly improve tissue hydration and reduce epithelial fragility. 4

Isolated vaginal dryness: initiate low‑dose vaginal estrogen unless contraindicated; if contraindicated or declined, offer vaginal DHEA; if both hormonal options are unsuitable, use vaginal moisturizers twice weekly. 1 / 4
Persistent symptoms despite systemic estrogen: add low‑dose vaginal estrogen or vaginal DHEA to address residual local symptoms. 1
Comorbid overactive bladder: low‑dose vaginal estrogen improves both genitourinary syndrome of menopause and urinary symptoms. 1

Any postmenopausal bleeding must prompt immediate endometrial assessment (transvaginal ultrasound and/or biopsy) before attributing the bleeding to atrophy, even in patients using low‑dose vaginal estrogen. 4
Low‑dose vaginal estrogen does not eliminate the risk of endometrial cancer; delayed evaluation may miss malignancy. 4
Skipping the 2‑week daily loading phase delays symptom relief and slows epithelial restoration; the loading phase is essential because atrophic tissue permits greater initial absorption, which normalizes as the epithelium heals. 3
Higher‑dose formulations (e.g., 25 µg tablets or creams ≥ 0.3 mg) result in higher systemic estradiol concentrations without providing additional symptomatic benefit. 3
When psychosocial or sexual health concerns coexist with genitourinary symptoms, referral to a qualified therapist is advised, as these factors markedly influence treatment outcomes. 2

Refer to a pelvic‑floor physical therapist when co‑existing pelvic‑floor dysfunction (urinary incontinence, defecatory dysfunction, or pelvic organ prolapse) is present. 2